{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:39:44Z","timestamp":1789799984549,"version":"4.0.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.autrev.2020.102523","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T12:36:57Z","timestamp":1584707817000},"page":"102523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":341,"title":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!"],"prefix":"10.1016","volume":"19","author":[{"given":"Ennio Giulio","family":"Favalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ingegnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Cincinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102523_bb0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2020.102523_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","author":"Tang","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.autrev.2020.102523_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.autrev.2020.102523_bb0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"New Engl J Medicine"},{"key":"10.1016\/j.autrev.2020.102523_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2020.102523_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0045","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.autrev.2014.08.026","article-title":"Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \u201canchor\u201d drug?","volume":"13","author":"Favalli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0050","series-title":"Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.autrev.2020.102523_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biology Rev Mmbr"},{"key":"10.1016\/j.autrev.2020.102523_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.autrev.2020.102523_bb0065","first-page":"26.919985","article-title":"Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov","volume":"2020","author":"Zhao","year":"2020","journal-title":"Biorxiv"},{"key":"10.1016\/j.autrev.2020.102523_bb0070","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza a H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2020.102523_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0080","unstructured":"G DS, Cardiology ES o. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers n.d."},{"key":"10.1016\/j.autrev.2020.102523_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","author":"Li","year":"2020","journal-title":"J Pharm Analysis"},{"key":"10.1016\/j.autrev.2020.102523_bb0090","article-title":"Adult haemophagocytic lymphohistiocytosis: a review","author":"Yildiz","year":"2020","journal-title":"Qjm Mon J Assoc Physicians"},{"key":"10.1016\/j.autrev.2020.102523_bb0095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102523_bb0100","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chest.2015.11.004","article-title":"Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis","volume":"149","author":"Seguin","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2020.102523_bb0105","article-title":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)","author":"Wan","year":"2020","journal-title":"Medrxiv"},{"key":"10.1016\/j.autrev.2020.102523_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102523_bb0115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.berh.2015.04.009","article-title":"Infections and arthritis","volume":"28","author":"Mathew","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0120","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2012.12.005","article-title":"Infectome: a platform to trace infectious triggers of autoimmunity","volume":"12","author":"Bogdanos","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0125","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3389\/fimmu.2017.01725","article-title":"Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of Tatarstan women","volume":"8","author":"Arleevskaya","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102523_bb0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-019-1977-9","article-title":"Respiratory viral infections and the risk of rheumatoid arthritis","volume":"21","author":"Joo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102523_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102523_bb0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102523_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2020.102523_bb0150","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102523_bb0155","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/ard.2006.057265","article-title":"Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis","volume":"66","author":"Franklin","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0160","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/acr.23426","article-title":"Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis","volume":"70","author":"Accortt","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2020.102523_bb0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0175","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102523_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0185","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102523_bb0190","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","article-title":"Comorbidities in rheumatoid arthritis","volume":"21","author":"Michaud","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102523_bb0200","first-page":"1","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Placebo-Controlled Clinical Trial Ann Intern Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0210","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102523_bb0215","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1373\/clinchem.2005.054460","article-title":"Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome","volume":"51","author":"Tang","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.autrev.2020.102523_bb0220","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Resp Crit Care"},{"key":"10.1016\/j.autrev.2020.102523_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","author":"Memish","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2020.102523_bb0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13054-019-2395-8","article-title":"The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis","volume":"23","author":"Ni","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2020.102523_bb0240","article-title":"Pharmacological agents for adults with acute respiratory distress syndrome","volume":"7","author":"Lewis","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2020.102523_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000375362","article-title":"Ibuprofen attenuates cardiac fibrosis in Streptozotocin-induced diabetic rats","volume":"131","author":"Qiao","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.autrev.2020.102523_bb0255","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102523_bb0260","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0270","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0275","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0280","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0290","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0295","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102523_bb0300","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Db Syst Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0305","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","article-title":"Long-term safety of abatacept in patients with rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4081\/reumatismo.2012.299","article-title":"Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents","volume":"64","author":"Bello","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2020.102523_bb0315","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1756283X10366368","article-title":"Anti-tumor necrosis factor therapy and influenza: keeping it in perspective","volume":"3","author":"Shale","year":"2010","journal-title":"Ther Adv Gastroenter"},{"key":"10.1016\/j.autrev.2020.102523_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0325","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.autrev.2019.102421","article-title":"The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis","volume":"19","author":"Favalli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0330","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/S2665-9913(20)30001-1","article-title":"Tofacitinib\u2019s infectious profile: concerns for clinical practice","volume":"2","author":"Favalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0335","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and Tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102523_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0345","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0350","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102523_bb0355","first-page":"485","article-title":"Real-world experience with tofacitinib for treatment of rheumatoid arthritis","volume":"37","author":"Caporali","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0360","doi-asserted-by":"crossref","first-page":"212595","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis","volume":"8","author":"Biggioggero","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.autrev.2020.102523_bb0365","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0370","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0375","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","author":"Liu","year":"2020","journal-title":"Acs Central Sci"},{"key":"10.1016\/j.autrev.2020.102523_bb0380","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2020.102523_bb0385","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2020.102523_bb0390","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"New Engl J Medicine"},{"key":"10.1016\/j.autrev.2020.102523_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0400","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2020.102523_bb0405","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/22221751.2019.1597644","article-title":"Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein","volume":"8","author":"Widjaja","year":"2019","journal-title":"Emerg Microbes Infec"},{"key":"10.1016\/j.autrev.2020.102523_bb0410","article-title":"A human monoclonal 1 antibody blocking SARS-CoV-2 infection","author":"Wang","year":"2020","journal-title":"Biorxiv"},{"key":"10.1016\/j.autrev.2020.102523_bb0415","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102523_bb0420","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1099\/0022-1317-4-2-203","article-title":"Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs","volume":"4","author":"Inglot","year":"1969","journal-title":"J Gen Virol"},{"key":"10.1016\/j.autrev.2020.102523_bb0425","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.autrev.2020.102523_bb0430","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"Paton","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0435","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/v10050268","article-title":"Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection","volume":"10","author":"Roques","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.autrev.2020.102523_bb0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.autrev.2020.102523_bb0445","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"105938","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.autrev.2020.102523_bb0450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0455","unstructured":"Chinese Clinical Trial Registry. 2020."},{"key":"10.1016\/j.autrev.2020.102523_bb0460","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.autrev.2020.102523_bb0465","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0470","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","author":"Diao","year":"2020","journal-title":"Medrxiv"},{"key":"10.1016\/j.autrev.2020.102523_bb0475","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.autrev.2020.102523_bb0480","series-title":"ChinaXiv:20200300026","article-title":"Effective treatment os severe COVID-19 patients with tocilizumab","author":"Xu","year":"2020"},{"key":"10.1016\/j.autrev.2020.102523_bb0490","article-title":"The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis","author":"Wang","year":"2020","journal-title":"Medrxiv"},{"key":"10.1016\/j.autrev.2020.102523_bb0495","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102523_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.02.007","article-title":"Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway","volume":"128","author":"Wang","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.autrev.2020.102523_bb0505","first-page":"401","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Struct Lond Engl 1993"},{"key":"10.1016\/j.autrev.2020.102523_bb0510","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2020.102523_bb0515","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102523_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.autrev.2020.102523_bb0525","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.autrev.2020.102523_bb0530","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2020.102523_bb0535","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2020.102523_bb0540","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102523_bb0545","first-page":"15","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"Biodrugs Clin Immunother Biopharm Gene Ther"},{"key":"10.1016\/j.autrev.2020.102523_bb0550","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2020.102523_bb0555","first-page":"144","article-title":"Corrigendum: a diverse range of gene products are effectors of the type I interferon antiviral response","volume":"525","author":"Schoggins","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2020.102523_bb0560","first-page":"23","article-title":"Viral inhibition of the IFN-induced JAK\/STAT Signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists","volume":"4","author":"Fleming","year":"2016","journal-title":"Nato Adv Sci Inst Se"},{"key":"10.1016\/j.autrev.2020.102523_bb0565","first-page":"73","article-title":"Current topics in microbiology and immunology","volume":"386","author":"Ayllon","year":"2014","journal-title":"Curr Top Microbiol"},{"key":"10.1016\/j.autrev.2020.102523_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013927","article-title":"Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling","volume":"5","author":"Jia","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102523_bb0575","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.autrev.2019.05.007","article-title":"Challenges in the treatment of rheumatoid arthritis","volume":"18","author":"Conigliaro","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0580","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","article-title":"The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives","volume":"16","author":"Favalli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102523_bb0585","doi-asserted-by":"crossref","first-page":"102399","DOI":"10.1016\/j.autrev.2019.102399","article-title":"Can we wean patients with inflammatory arthritis from biological therapies?","volume":"18","author":"Edwards","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:28Z","timestamp":1761599908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":115,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1568997220300781"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102523","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102523"}}